Cite
FRI0184 Cost-effectiveness and budget impact of certolizumab pegol against the current mix of anti-tnf treatments in an outcomes-based risk-sharing scheme in finland
MLA
Riitta Luosujärvi, et al. “FRI0184 Cost-Effectiveness and Budget Impact of Certolizumab Pegol against the Current Mix of Anti-Tnf Treatments in an Outcomes-Based Risk-Sharing Scheme in Finland.” Annals of the Rheumatic Diseases, vol. 72, June 2013, p. A434.2-A434. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........81eb4220ce0fe9cc24cb3508928c80e4&authtype=sso&custid=ns315887.
APA
Riitta Luosujärvi, Kari Puolakka, M. Taiha, Oana Purcaru, E. Soini, & C. Asseburg. (2013). FRI0184 Cost-effectiveness and budget impact of certolizumab pegol against the current mix of anti-tnf treatments in an outcomes-based risk-sharing scheme in finland. Annals of the Rheumatic Diseases, 72, A434.2-A434.
Chicago
Riitta Luosujärvi, Kari Puolakka, M. Taiha, Oana Purcaru, E. Soini, and C. Asseburg. 2013. “FRI0184 Cost-Effectiveness and Budget Impact of Certolizumab Pegol against the Current Mix of Anti-Tnf Treatments in an Outcomes-Based Risk-Sharing Scheme in Finland.” Annals of the Rheumatic Diseases 72 (June): A434.2-A434. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........81eb4220ce0fe9cc24cb3508928c80e4&authtype=sso&custid=ns315887.